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1

CHAPTER I: Introduction
In the liver, lipid content is regulated by dietary FA (FA) or carbohydrate
uptake, as well as hepatic biosynthesis, esterification, oxidation, and export of FA (1,
2). After consumption, dietary carbohydrates are both used for normal functions and,
if present in excess, stored for later use. Enzymes involved in glycolytic and lipogenic
pathways are dynamically regulated at both transcriptional and post-translational
levels by various factors such as substrate concentrations and hormones (3).
Metabolic signals, such as an excess of FA, glucose, or insulin, can regulate the
activity or abundance of key transcription factors to modulate hepatic lipid metabolism
(1). Many liver-specific transcription factors have been identified as prospective
targets for de novo lipogenesis and FA oxidation, including sterol regulatory element
binding protein-1c

(SREBP-1c) ,

peroxisome

proliferator-activated

receptors

(PPARs), liver X receptor (LXRα), and carbohydrate-responsive element-binding
protein (ChREBP) (4-7). These factors integrate signals from multiple pathways and
organize the activity of the metabolic enzymes necessary for hepatic lipid metabolism
with the supply of energy and FA. Cyclic-AMP response element binding protein H
(CREBH) is an endoplasmic reticulum (ER)-membrane-bound transcription factor that
is preferentially expressed in liver (8-10). CREBH is a major player in regulating lipid
and glucose metabolism in the liver. Metabolism of these two classes of molecules is
important in maintaining energy production, usage and storage in individual cells as
well as maintaining energy homeostasis at the systemic level(11, 12). Disturbances
to this delicate balance may lead to energy imbalances and serious health
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consequences, particularly non-alcoholic fatty liver disease (NAFLD) or non-alcoholic
steatohepatitis (11-13).
1.1 Hepatic Energy Metabolism
Hepatocytes, the parenchymal cell of the liver, exhibit a unique strategies for
processing metabolites (13-18). Hepatocytes carry out multiple metabolic processes
including glycolysis, gluconeogenesis, lipolysis, lipogenesis, FA oxidation, and
ketogenesis (Figure 1). Glycolysis is the breakdown of glucose to pyruvate, which is
carried out in ten steps (19). During glycolysis, the conversion of glucose to glucose6-phosphate, the conversion of fructose-6-phosphate to fructose-1,6-bisphosphate
and the conversion of phosphoenolpyruvate (PEP) to pyruvate, are regulated by the
enzymes glucokinase, phosphofructokinase, and pyruvate kinase, respectively. The
end product of glycolysis, pyruvate, can be irreversibly converted to acetyl coenzyme
A (acetyl CoA), a metabolite involved in multiple metabolic pathways (20).

Figure 1. Simplified model of energy metabolism. Glucose taken from blood enters
the glycolytic pathway to generate pyruvate and glycogen. Glucose may be
generated by the gluconeogenesis or glycogenolysis. Acetyl CoA may convert
between ketone bodies or triglycerides. Acetyl CoA also may generate ATP via the
TCA cycle and oxidative phosphorylation (not shown).
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Gluconeogenesis is the production of glucose from non-sugar sources (19,
21). The source used may be lactate, pyruvate, or amino acids. Hepatocytes utilize
lactate produced in peripheral tissues via anaerobic respiration. The multistep
process of gluconeogenesis is regulated by four enzymes: glucose-6-phosphatase,
fructose-1,6-bisphosphatase,

pyruvate

carboxylase,

and

PEP

carboxykinase

(PEPCK). Interestingly, the rate of activity of both glucose-6-phosphatase and
PEPCK are primarily regulated at the transcriptional level. Glucose can also be
stored as or generated from glycogen, a polysaccharide that consists of branched
chains of glucose molecules (22). These chains can be quickly broken down to
produce glucose that can enter the bloodstream or the glycolytic pathway. The
breakdown

of

glycogen,

known

as

glycogenolysis,

is

regulated

by

the

phosphorylation of its rate-limiting enzyme, glycogen phosphorylase (22). Excess
levels of glucose are stored as glycogen via the glycogen synthesis pathway. This
pathway is regulated by phosphorylation of the glycogen synthase enzyme.
In addition to its involvement in the glucose metabolism, pyruvate also can be
converted irreversibly to acetyl-CoA by the pyruvate dehydrogenase complex (23).
Acetyl-CoA is a predecessor metabolite of both lipid and ketone body production.
Increased levels of acetyl-CoA increase lipogenesis. Activation of the enzyme, acetylCoA carboxylase, induces the conversion of acetyl-CoA to malonyl-CoA which is then
converted to malonyl-ACP and shuttled into the mitochondria. Through multiple
conversion processes, the malonyl-ACP molecules are condensed to produce a FA
chain (24). FA chains are joined to a glycerol-3-phosphate back bone to form a
triglyceride (TG). After a TG is formed, it may be stored in cytoplasmic lipid droplets
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or incorporated into VLDL particles and secreted into the blood. Additionally, in a
state of energetic need, TG can also be hydrolyzed to release the esterified FA.
These FA are destined to undergo oxidation. Conversion of carbohydrates to TG
involves two steps: glycolysis which generates acetyl-CoA from glucose, and
lipogenesis which converts acetyl-CoA to FA.
Retrieving energy from TG requires hydrolysis of the TG molecule to yield the
stored FA. Lipolysis occurs in three steps, each of which releases one FA chain (25).
First, the TG is cleaved to produce one FA chain and a diacylglyceride. Next, the
diacylglyceride is cleaved to produce another FA and a monoacylglyceride. The final
step is the cleavage of the last FA chain and a glycerol molecule. Glycerol can be
converted to dihydroxyacetone phosphate to feed into the glycolytic and
gluconeogenic pathways. TG carried by lipoproteins must also undergo lipolysis to
release FA which can be taken up by the target cells. After free FA have been
released from the TG, they undergo oxidation (26). The primary method of FA
oxidation is mitochondrial β-oxidation. FA oxidation is a primary source of energy
during fasting. Oxidation of FA yields acetyl-CoA. FA that cross the plasma
membrane are rapidly converted to fatty acyl-CoA. This process is known as FA
activation.
Ketogenesis is the process by which acetyl-CoA is used to generate ketone
bodies (27, 28). Ketone bodies are metabolites that can be converted to energy by
converting them back to acetyl-CoA. Ketogenesis occurs mainly in the liver during
prolonged states of fasting, when available blood glucose levels are low. During
fasting, ketones generated in the liver are used as energy in peripheral tissues,
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especially the brain which cannot produce energy from FA oxidation. Insulin signaling
represses ketogenesis. There are three types of ketone bodies: acetoacetone,
acetone, and 3-hydroxybutyric acid (BOH). The rate of conversion from acetyl-CoA to
these ketone bodies is limited by the enzyme HMG-CoA synthase, which converts
acetoacetyl-CoA to HMG-CoA. The first ketone body that can be formed from acetylCoA is acetoacetate. Acetoacetate can generate acetone by non-enzymatic
decarboxylation. Acetoacetate can also generate BOH in a reaction catalyzed by the
enzyme D-β-hydroxybutryate dehydrogenase (BDH1). Typically, during long-term
fasting, BOH is the most abundant ketone body in serum (29, 30).
1.2 Hepatic Energy Maintenance
The liver is an organ that is heavily involved in energy homeostasis. The liver
monitors and maintains metabolite levels through complex regulatory mechanisms.
Hormones, such as insulin and glucagon, induce signaling pathways in hepatocytes
that lead to altered metabolic profiles. Insulin signaling decreases blood sugar, while
up-regulating glycolysis, glycogenesis, and lipid storage (31). Binding of insulin to the
insulin receptor induces autophosphorylation and activation of the receptor. Activation
of this transmembrane receptor induces recruitment, phosphorylation and activation
of insulin receptor substrate (IRS) proteins. Active IRS1 and IRS2 initiate a signaling
cascade that induces glucose receptor transport from the Golgi apparatus to the cell
membrane to increase glucose uptake. Additionally, the IRS substrates activate PI3
kinase and, consequently, protein kinase B (AKT). AKT induces both glycogen
synthesis and lipid storage (Figure 2).
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Glucagon is another metabolic hormone that is produced in the pancreas (32).
Production of glucagon is induced by fasting conditions leading to decreased levels of
blood glucose. Glucagon is released into the bloodstream where it interacts with
hepatic receptors. Hepatocytes under the regulation of glucagon exhibit upregulated
gluconeogenesis

and

glycogenolysis

resulting

in

increased

blood

glucose.

Additionally, both lipolysis and ketogenesis are upregulated in hepatocytes under
glucagon signaling (33, 34).

Figure 2. Diagram of insulin signaling in the hepatocyte. Insulin activates insulin
receptors (IR), initiating a signaling cascade resulting in increased glucose uptake via
the Glucose transporter (GLUT), lipogenesis and glycogen storage, as well as
decreased gluconeogenesis.
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Glucagon signaling functions through activation of the glucagon receptor, a Gprotein coupled receptor. Activation of this receptor results in recruitment of GTP to
the associated G-protein complex. This allows the alpha subunit of the G-protein
complex to dissociate from the beta and gamma subunits and activate adenylate
cyclase. Adenylate cyclase is an enzyme that converts ATP to cyclic AMP (cAMP).
Increased intracellular levels of cAMP result in activation of protein kinase A (PKA).
Active PKA initiates multiple signaling cascades, including activation of the CREB
transcription factor and phosphorylase kinase. Targets of CREB transcriptional
regulation include Pepck and G6pc, two major players in the gluconeogenic pathway.
Phosphorylase kinase induces signaling cascades that both induce glycogenolysis
and inhibit glycogen synthesis.
In contrast to incoming hormone signals, the liver is also responsible for
producing hormones that deliver signals on the systemic level, as well as, to specific
peripheral organs. These liver-derived hormones include hepcidin, betatrophin, and
fibroblast growth factor 21 (FGF21) (35-37). Hepcidin is a powerful regulator of iron
concentration. FGF21 is a systemic regulator of energy metabolism. Hepcidin and
FGF21 are systemic regulators, while betatrophin acts as a blood lipid regulator by
regulating serum TG levels, possibly through promoting ANGPTL3 cleavage (38).
1.3 Transcriptional Regulators of Hepatic Energy Metabolism
Hepatic energy metabolism is often regulated at the transcriptional level by
modulating transcription of mRNAs of key rate-limiting enzymes. This regulation can
be observed in various pathways, including gluconeogenesis, lipolysis, lipogenesis,
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FA metabolism, and ketogenesis. Metabolic stress, in the form of hormone signaling
or altered metabolite levels, can trigger these changes.
The rate of gluconeogenesis is regulated by activity of two enzymes, PEPCK
and G6PC, the catalytic subunit of the glucose-6-phosphatase enzyme complex (21).
Both Pepck and G6pc contain segments of DNA known as insulin response elements
in their promoter regions. This element allows the transcription factor, FOXO1, to bind
and increase the transcriptional rate of these genes. AKT phosphorylation, induced
by the insulin signaling cascade, results in increased AKT activity. AKT irreversibly
phosphorylates FOXO1 on the promoter region of the gluconeogenic genes, causing
FOXO1 to dissociate from the DNA and exit the nucleus. This causes a decrease in
transcription of both Pepck and G6pc, and subsequently, inhibits gluconeogenesis
(Figure 2).
FA metabolism is the avenue by which cells maintain homeostasis of FA levels
by way of oxidation and synthesis of FA. The balance of these opposing processes is
maintained by transcriptional regulation of key enzymes and activation of pertinent
transcription factors. Dietary intake of lipid metabolites is a major factor in regulating
the expression and activation of these proteins. The peroxisome proliferatoractivating receptor (PPAR) family, liver x receptor alpha (LXRα), carbohydrate
response element binding factor (ChREBP), and sterol response element-binding
protein 1c (SREBP1c) are integral transcription factors in the maintaining FA
homeostasis (39).
PPAR family members PPARα is a nuclear receptor that is important in the
maintenance of lipid homeostasis. PPARα activity in the liver can be induced by
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fasting or influx of dietary lipids (40, 41). This allows PPARα to act as a FA sensor
and induce FA oxidation (42). Transcriptional targets of PPARα include,
apolipoproteins, which are involved in lipolysis, and carnitine palmitoyl-transferases,
which are involved in FA oxidation (43-46). Additionally, PPARα-null mice display a
defective fasting response characterized by low ketone and glucose levels in blood
(45).
LXRα is an isoform of LXR that is highly expressed in liver tissue. LXRα is a
key regulator of hepatic lipogenesis and is induced by FA (47, 48). Lxrα-null mice
demonstrate defective in FA synthesis and lipogenesis, coinciding with downregulation of the Srebp-1, stearoyl CoA desaturase-1 (Scd1), and FA synthase (Fasn)
genes (49). SREPB1c is a transcription factor that targets genes involved in de novo
lipogenesis. Unlike SREBP1a, another SREBP1 isoform, SREBP1c is not regulated
by intracellular sterol concentration. Instead SREBP1c regulation is controlled by
insulin signaling (50). SREBP1c targets genes required for glycolysis and lipogenesis
(51). Upon activation, the ER-membrane bound SREBP1c protein migrates to the
Golgi and is cleaved, releasing the active cytosolic portion of the protein which acts
as a transcription factor (52). ChREBP is a transcription factor that is activated in
response to glucose (53). Upon activation, ChREBP induces lipogenesis by upregulating Scd1, Fasn, and acetyl-CoA carboxylase 1 (54, 55). Knockdown of
ChREBP in ob/ob mice resulted in reduced hepatic steatosis and increased insulin
sensitivity (56).
1.4 Non-alcoholic fatty liver disease (NAFLD)
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The above-mentioned methods of regulation describe a delicate balancing act
that relies on proper function in all metabolic pathways to maintain homeostasis.
Imbalances in hepatic energy metabolism result in disruption of this homeostasis. If
the disruption results in excess lipid accumulation in the liver, NAFLD can occur.
NAFLD is defined by hepatic steatosis in an individual who does not excessively
consume alcohol (57). Inhibition or deletion of some genes involved in lipid
metabolism can protect against development of NAFLD (58). For example, the Scd1null mouse model is resistant to diet-induced hepatic steatosis (59). Prolonged or
harmful disruptions may result in NAFLD, a disease state in the liver defined by an
excessive accumulation of fat. NAFLD places an individual at risk for NASH, a more
advanced form of liver disease that involves both steatosis and inflammation of the
liver.
NASH develops as a progression of NAFLD. The progression of a healthy liver
to NAFLD to NASH is described by the two-hit model (60) (Figure 3). NAFLD is the
result of TG buildup in the liver. This buildup is caused by an inability of the liver to
balance import and synthesis of TG with the export and degradation or TG. The
imbalance is the first hit and is often a result of increased lipid delivery to the liver,
increased hepatic de novo lipogenesis, or insulin resistance. After the first hit, a liver
that has NAFLD is susceptible to a second hit. The second hit is a stress-inducing
factor that results in inflammation. These factors include oxidative stress, endotoxins,
saturated FA, or inflammatory cytokines (61, 62). Healthy livers are resistant to
second hits, but livers with NAFLD are at higher risk for liver damage caused by
second hit exposure.

11

Increased FA delivery;
hepatic lipogenesis;
Insulin resistance

Oxidative stress;
Inflammatory cytokines;
Saturated FA; Endotoxin

First hits

Normal liver

Fatty liver
(Steatosis)

Second hits

Steatohepatitis

Figure 3. Illustration of the two-hit model of NASH pathology.

NAFLD does not always present with symptoms, but NAFLD patients do
commonly suffer from fatigue (63). Additionally, NAFLD often presents with insulin
resistance (64). Patients with NAFLD present altered liver enzyme levels, particularly
those of aspartate transaminase (AST) and alanine transaminase (ALT). In healthy
individuals, the ratio of AST to ALT is less than one. Upon the onset of NAFLD, that
ratio increases (57, 65). Patients with NASH often present with an AST to ALT ratio
that is higher than one, but a proper diagnosis of NASH must be made by liver biopsy
(66, 67).
1.5 CREBH
The ER is an organelle that is heavily involved in protein folding and plays an
important role in stress response (68). The ER membrane contains bound signaling
molecules that respond to incoming metabolic stress to regulate lipid and glucose
metabolism. CREBH is a bZip transcription factor that is primarily expressed in the
liver (10). It is localized in the ER of hepatocytes as an inactive, full-length,
membrane-bound protein. In order to become an active transcription factor, CREBH
must be cleaved, releasing the cytosolic portion of the protein (9). Activation can be
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caused by dietary, ER, or inflammatory stress conditions, such as proinflammatory
cytokines TNFα, IL6, and IL1β, bacterial endotoxin lipopolysaccharide, insulin
signaling, saturated FA, nutrient starvation, or AHF diet feeding (9, 12). CREBH
migrates from the ER to Golgi apparatus where it is cleaved by Site-1 and Site-2
proteases in a manner similar to that observed in the activation of SREBPs (9).
Afterwards, the active, cytosolic region of CREBH may enter the nucleus to act as a
transcription factor and induce expression of downstream target genes involved in
lipid and glucose metabolism (Figure 4).

Figure 4. Diagram of CREBH activation. Upon stress, CREBH migrates from the ER
to the Golgi Apparatus to undergo cleavage. The cleaved portion of CREBH induces
transcription of downstream targets.
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CREBH regulates many lipid and glucose metabolic pathways (13). In fact,
previous studies performed in our laboratory have shown that this multi-faceted
behavior maintains homeostasis by inducing opposing metabolic processes, such as
lipolysis and lipogenesis or FA elongation and oxidation (12). Upon longer-term
feeding of AHF, more advanced manifestations of metabolic syndrome become
apparent. Upon six-month feeding of AHF, CrebH-null mice develop symptoms of
NASH not found in wild-type mice under the same feeding conditions (12).
Hepatocytes from these diet-treated CrebH-null mice exhibit increased size and lipid
droplet content. Livers from these mice demonstrate inflammation and morphological
changes accompanying the increase in lipid content. Additionally, serum TG levels
are increased in CrebH-null mice compared to wild-type mice after diet treatment.
This elevated level of serum TG content is known as hypertriglyceridemia. CREBH
was later shown to regulate to expression of ApoA4, a gene involved in lipolysis (69).
The role of CrebH in metabolite regulation is not limited to mice. A 2012 study
showed that rare variants in the human CREBH gene contribute to the development
of hypertriglyceridemia in human patients (70).
CREBH has been shown to play a vital role lipogenesis upon induction of ER
stress. Primary hepatocytes from wild-type and CrebH-null mice were treated with the
ER stress inducing substances, tunicamycin and palmitic acid (12). Wild-type primary
hepatocytes exhibited the development of lipid droplets indicative of functional ER
stress-induced lipogenesis. Primary hepatocytes from CrebH-null mice were unable
to produce lipid droplets at levels comparable to cells from the wild-type mice.
CREBH was also shown to transcriptionally regulate the Fsp27 gene, which is
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important in lipid droplet formation (71). These results indicate a complex and, at
times, paradoxical role for CREBH in lipid metabolism.
CREBH has also been demonstrated as major player in gluconeogenesis in
the liver. Lee et al. showed that CrebH mRNA, along with that of gluconeogenic
enzymes, was upregulated during fasting (13). Additionally, CrebH overexpression
upregulated the mRNA levels of Pepck and G6pc. In rat primary hepatocytes, CrebH
overexpression increased glucose output. CrebH-knockdown reduced fasting blood
glucose levels in both wild-type and hyperglycemic db/db mice. These results show
that CREBH activation during fasting induces gluconeogenesis.
1.6 FGF21
FGF21 is a metabolic hormone that is expressed preferentially in the liver and
regulates lipid and glucose metabolism at a systemic level (72). It is a member of the
FGF family of proteins that is commonly associated with cell proliferation. FGF21
differs from this convention by not playing a role in cell proliferation and instead
regulating energy metabolism pathways. Activity of FGF21 is associated with
antiobesity and antidiabetic effects (73, 74). These characteristics have caused
FGF21 to be a focus of clinical trials.
In mice, FGF21 is secreted by multiple organs, though primarily liver, in
response to metabolic stress. These stresses include fasting, high-fat diet, and highsucrose diet. Under high-fat diet and fasting conditions, Fgf21 expression is upregulated by PPARα (75, 76). Upon secretion, the FGF21 protein enters circulation
where it signals to target tissues, which include liver, adipose, pancreas and brain.
Signaling is carried out by interaction with β-Klotho and FGF receptor (77). After
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FGF21 has entered circulation, the protein half-life is approximately 30 minutes, but
its metabolic effects last for 24 hours in peripheral tissues (78, 79). In human
hypertriglyceridemia patients, fenofibrate treatment resulted in increased serum
FGF21 levels (80).
Under fasting conditions, FGF21 activity stimulates FA oxidation and
ketogenesis (37). During the fed state, FGF21 produced in the adipose tissue
regulates Pparγ expression. The metabolic consequences of FGF21 signaling vary
from tissue to tissue. In liver, FGF21 signaling induces gluconeogenesis, FA
oxidation, and ketogenesis. Adipose tissue undergoes decreased lipolysis and
increased thermogenesis and glucose uptake in response to FGF21 signaling.
FGF21 signaling in brain alters behavior, increasing food intake and energy
expenditure.
Due to its effects on multiple tissues and control over metabolic function,
FGF21 has been the focus many studies aimed at rescuing disease phenotypes. In
obese mice, prolonged administration of FGF21 protein resulted in pronounced
weight loss (81). Furthermore, overexpression of Fgf21 in mouse liver protected
these mice from diet-induced weight gain (79). In mice that have developed dietinduced NAFLD, exogenous FGF21 protein administration was proven effective in
reducing liver lipid content (82). In diabetic cynomolgus monkeys, FGF21 mimetic
administration improved the overall serum lipid profile (83). These animals showed
decreased serum TG, cholesterol and LDL content. This improvement coincided with
decreased fasting serum glucose and insulin levels and an increase in serum HDL
levels. Obese mice, while responsive to exogenous FGF21 administration, have
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elevated FGF21 serum levels and are FGF21-resistant (84). Elevated serum levels of
FGF21 in humans have been associated with hepatic steatosis, insulin resistance,
hypertriglyceridemia, and type 2 diabetes (37).
The promising results of rescue experiments in animal disease models,
coupled with the mildness of side effects, FGF21 has been a focal point for
therapeutic research. Research in this area has aimed toward improving stability of
the protein in circulation, sensitizing tissues to FGF21 signaling, and increasing
bioavailability of administered protein (79, 85, 86). Despite evidence of FGF21
resistance in patients who are most likely to benefit from the treatment, therapeutic
FGF21 administration remains a viable avenue of research, due to effectiveness of
FGF21 treatment in FGF21 resistant animal models. Currently, an FGF21 analogue,
called LY2405319, has shown promise in clinical testing (87, 88).
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CHAPTER II: Defining the Phenotype of CrebH-null Mice Under
Metabolic Stress
2.1 Summary
In this chapter, we define the phenotype of CrebH-null mice under three
sources metabolic stress: fasting, AHF diet, and high-sucrose diet. CrebH-null mice
were shown to be susceptible to hyperlipidemia during fasting and AHF diet-feeding.
These mice were also defective in ketogenesis. Quantitative real-time PCR analysis
reveals CREBH-mediated regulation of genes involved in lipid clearance and
ketogenesis. CrebH-null mice have been shown to be more susceptible to AHF dietinduced non-alcoholic fatty liver disease than wild-type counterparts. Enzymatic and
histological analysis of liver tissue from AHF diet-fed CrebH-null and wild-type mice
indicated elevated levels of lipid content in CrebH-null mice. High-sucrose dietfeeding is proposed as a novel inducer of CREBH activity. After 5 weeks of highsucrose feeding, evidence suggests that CrebH-null mice were protected from dietinduced insulin resistance. Additionally, CREBH regulates expression of the
metabolic hormone, Fgf21, under fasting, high-sucrose diet, and AHF diet stresses.
CREBH-mediated regulation of Fgf21 was confirmed by gain-of-function analysis in
mice expressing exogenous CREBH.
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2.2 Materials and methods
Materials
Chemicals were purchased from Sigma unless indicated otherwise. Synthetic
oligonucleotides were purchased from Integrated DNA Technologies, Inc. (Coralville,
IA). Human insulin was purchased from Eli Lilly (Indianapolis, IN). Antibody against
murine CREBH was made in our laboratory as previously described (9). Mouse
monoclonal anti-FGF21 antibody and FGF21 ELISA kit were from R & D Systems,
Inc. (Minneapolis, MN). Kits for measuring TG, FA, and the ketone body, 3hydroxybutyric acid were purchased from BioAssay Systems, Inc. (Hayward, CA).
Mouse experiments
The CrebH-null mice with deletion of exons 4–7 of the CrebH gene have been
previously described (8). Wild-type control mice on a C57Bl/6J background of
approximately 3-months of age were used for the metabolic diet study. Unless
otherwise stated, all animals were fed ad libitum with Laboratory Rodent Diet 5001
from Lab Diet. For the atherogenic high-fat (AHF) diet study, the AHF diet (16% fat,
41% carbohydrate, 20% protein, 1.25% cholesterol , supplemented with 0.5% sodium
cholate by weight) was purchased from Harlan Laboratories, Inc. (TD.88051). For the
high-sucrose diet study, the high-sucrose diet (5.2% fat, 18.3% protein, and 61.7%
carbohydrate by weight, with 53% of carbohydrate calories coming from sucrose) was
provided by Harlan Laboratories Inc. (TD.88122). All the animal experiments were
approved by the Wayne State University IACUC committee and carried out under the
institutional guidelines for ethical animal use. For all fasting procedures, mice were
housed in cages containing Pure-o’Cel bedding. Mice were provided water, but no
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food for 6, 12, 14, or 24 hours. Tissue collection or glucose tolerance test were
performed immediately after the fasting period.
Food intake and fat mass measurements
The CrebH-null and wild-type mice were subjected to food intake
measurement under the normal chow diet. Food consumption was determined by
measuring diet weights every 12 hours. Daily food intake was determined based on
food consumption in 24 hours, measured daily for one week. The whole body fat
mass of the CrebH-null and wild-type mice was determined by using the EchoMRI
system for living animals according to manufacturer’s instruction (Echo Systems,
Houston, TX).
Measurement of mouse lipid contents
Liver tissue and blood plasma samples were isolated from the mice under the
normal chow diet, after fasting, or after the AHF diet. To determine hepatic TG levels,
approximately 100 mg liver tissue was homogenized in PBS followed by
centrifugation. The supernatant was mixed with 10% Triton-100 in PBS for TG
measurement using a commercial kit (BioAssay Systems, Hayward, CA). Mouse
blood plasma samples were subjected to quantitative analyses of plasma TG, total
cholesterol, HDL, and LDL as previously described (12). Levels of the ketone body
metabolite, 3-hydroxybutyric acid in the plasma were determined using commercial
kits (BioAssay Systems).
Oil-red O staining
Frozen liver tissue sections were stained with Oil-red O for lipid contents
according to standard protocol. Briefly, frozen liver tissue sections of 8 microns were
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air-dried, and then fixed in formalin. The fixed sections were rinsed with 60%
isopropanol before they were stained with freshly prepared Oil-red O solution for 15
minutes. After Oil-red O staining, liver sections were rinsed again with 60% isopropanol
followed by washing with water before subjected to microscope analysis.
Quantitative real-time PCR
For real-time PCR analysis, the reaction mixture containing cDNA template,
primers, and SYBR Green PCR Master Mix (Applied Biosystems) was run in a 7500
Fast Real-time PCR System (Applied Biosystems, Carlsbad, CA). Fold changes of
mRNA levels were determined after normalization to internal control β-actin mRNA
levels. The sequences of real-time PCR primers used in this study are shown in
appendix A.
Adenovirus injection
Adenovirus-expressing GFP (Ade-GFP) or the activated CREBH (AdeCREBH) were injected to wild-type mice through tail-vein injection. Approximately 1 ×
1010 PFU of adenovirus in 0.3 ml PBS were injected into a mouse of approximately
20 gram body weight. Three days after the injection, the liver tissues and blood
samples were collected from the CrebH-null and wild-type control mice under feeding
or fasting condition for further analyses.
FGF21 Enzyme-linked Immunosorbent Assay (ELISA)
Mouse blood serum were collected for FGF21 ELISA analysis. The analysis
was performed using mouse monoclonal anti-FGF21 antibody and FGF21 ELISA kit
from R & D Systems, Inc. (Minneapolis, MN) according to the manufacture’s
instruction.
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Glucose tolerance test (GTT) and insulin tolerance test (ITT)
Glucose tolerance was measured after intraperitoneal (i.p.) injection of 2mg
glucose/gram body weight into overnight-fasted CrebH-null and wild-type control
animals. For the insulin tolerance test, mice were fasted for 4 hours before i.p.
injection of human insulin (0.75 mU/g body weight). Blood glucose levels were
measured from tail blood using an OneTouch Ultra glucometer (Johnson & Johnson).
Statistics
Experimental results are shown as mean ± SEM (for variation between
animals or experiments). The mean values for biochemical data from the
experimental groups were compared by a paired or unpaired, 2-tailed Student’s t test.
Statistical tests with P < 0.05 were considered significant.
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2.3 Results
Previous studies have shown that CREBH cleavage and activation can be
effected by ER stress, inflammatory stimuli, and metabolic stress (8, 9, 12). In
addition to mediating hepatic acute-phase response, CREBH has been shown to
have a drastic effect on the ability of mice to cope with metabolic stress caused by
high-fat diet feeding. To further explore the role of CREBH on physiological
adaptation to metabolic stress, CrebH-null and wild-type control mice were exposed
to fasting conditions or fed with the AHF or high-sucrose diet.

Figure 5. Metabolite levels in serum
from wild-type and CrebH-null mice
under metabolic stress. Levels of (A)
triglyceride, (B) fatty acid, and (C) BOH
were analyzed under feeding, fasting,
and AHF diet conditions. Each bar
denotes the mean SEM (n = 8 WT or
KO mice under feeding or fasting
condition; n = 6 WT or KO mice under
the AHF diet). *, P ≤ .05; **, P ≤ .01

Fasting has been previously shown to induce CREBH activity (13, 89). Serum
TG were elevated in CrebH-null mice compared to those of the wild-type control
under feeding conditions, but serum FA and BOH levels remained similar between
the groups (Figure 5). However, after overnight fasting, more discrepancies between
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the CrebH-null and wild-type mice serum metabolites begin to manifest. These
include increased levels of serum TG and FA that coincide with decreased levels of
BOH in the CrebH-null mice. After feeding wild-type and CrebH-null mice with an
atherogenic high fat diet for 6 months, CrebH-null mice possess higher levels of
hepatic TG compared to wild-type mice, as indicated by both Oil-red staining of liver
tissue sections and quantitative enzymatic analysis of hepatic TG levels (Figure 6).
Additionally, serum TG and FA levels were significantly increased in CrebH-null mice,
while serum BOH levels were lowered in these mice (Figure 5). Furthermore, CrebHnull mice exhibited decreased body fat mass compared to wild-type mice under a
normal chow diet (Figure 7B). This reduction in fat mass coincided with a slightly
decreased weight compared to wild-type mice (Figure 7A). Food consumption was
measured under these conditions, and CrebH-null and wild-type mice were found to
consume similar amounts of food (Figure 7C). This finding excludes food intake as a
factor in the differences in body and fat mass observed in our testing groups.

Figure 6. Hepatic lipid content analysis after AHF diet. (A) Oil Red O staining of liver
tissue sections from mice after 6 months of AHF diet feeding. CrebH KO mice exhibit
drastically increased lipid droplet content as well as hepatocyte size compared to
wild-type mice. (B) Quantitative, colorimetric assay of hepatic triglyceride content. ** p
≤ 0.01.
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Figure 7. Physiological comparison of wild-type and CrebH-null mice after AHF dietfeeding. (A) Body weight comparison (B) Body fat mass determined by MRI. (C) Food
consumption. * p ≤ 0.05.

Previously, we performed gene microarray analysis with CrebH-null and wildtype control mice fed either normal chow or AHF diet (12). The microarray analysis
implicated that most CREBH-regulated genes are involved in lipid metabolism,
specifically TG metabolism, cholesterol and sterol biosynthesis, FA oxidation, and
ketogenesis. In order to identify genes that undergo CREBH-mediated, fastinginduced upregulation, wild-type and CrebH-null mice were exposed to feeding or 16hour fasting conditions. Liver tissues were collected from these mice and quantitative
real-time PCR was performed to identify CREBH-regulated genes (Figure 8). My
analysis identified that the genes Fgf21, apolipoprotein (Apo) C-II (ApoC2), ApoA5,
and lactate dehydrogenase A (Ldha) are regulated by CREBH in mouse liver under
fasting conditions. Expression levels of these genes did not differ in wild-type and
CrebH-null mice under feeding conditions. Upon fasting, wild-type mice showed a
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modest but significantly higher level of expression for these targets than CrebH-null
mice.
Just as the targets of CREBH regulation varied under differing metabolic
stresses, the fasting-induced effect of CREBH on target gene expression may vary
under differing fasting conditions. In our experiment, groups of three male wild-type
mice were paired with groups of three male CrebH-null mice and fasted for 6, 12 or
24 hours beginning at 6 pm. Immediately after fasting, mice were sacrificed and liver
tissue samples were collected. Fed wild-type and CrebH-null mice liver tissue
samples were collected as controls. Quantitative, real-time PCR was performed to
determine hepatic gene expression. In this experimental setting, I identified that
CREBH regulates hepatic expression of the Fgf21, Bdh1, and Ldha genes in mice
upon different periods of fasting (Figure 9). Fed wild-type and CrebH-null mice
showed relatively low baseline expression levels of Fgf21 mRNA. Fgf21 upregulation
was strongest in the 6- and 12-hour fasted wild-type mice, but showed a more
modest increase in the 24-hour fasted wild-type group. In contrast, CrebH-null mice
displayed a similar pattern in Fgf21 expression pattern, but mRNA levels were
roughly 10-fold lower than in their wild-type counterparts (Figure 9).
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Figure 8. Quantitative real-time PCR analysis of fasting-induced gene transcriptional
regulation in CrebH-null (KO) and wild-type (WT) control mice under fasting and fed
conditions. Fold changes of mRNA expression levels were calculated after
normalization to that of β-actin. Bars denote mean values ± SEM (n=3). * p≤ 0.05.

Expression levels of the Bdh1 and Ldha mRNAs were similar in both wild-type
and CrebH-null mice under feeding conditions. However, under 12-hour fasting,
expression levels of the Bdh1 and Ldha mRNA in CrebH-null mice were significantly
lower than those in the control mice (Figure 9). This difference persisted in Bdh1
expression levels after 24-hour fasting, as well.

27

Figure 9. Quantitative real-time PCR analysis of variable-length fasting-induced gene
expression in CrebH-null (KO) and wild-type (WT) control mice. Liver tissue mRNA
samples from wild-type and CrebH-null mice under fed and 6-, 12-, and 24-hour
fasting conditions were compared. Fold changes of mRNA expression levels were
calculated after normalization to that of β-actin. Bars denote mean values ± SEM
(n=3). * p≤ 0.05. ** p≤0.01.

In addition to fasting, I tested the regulation of FGF21 expression by CREBH
under metabolic stress-inducing diets. Previous studies have shown that Fgf21
expression is augmented by diets that are high in sucrose (90). To test whether
CREBH plays a role in this upregulation, wild-type and CrebH-null mice were fed a
normal or high-sucrose diet for 5 weeks. After the feeding period, mice were
euthanized and mouse livers were collected. Quantitative real-time PCR analysis
revealed that Fgf21 expression shows a marked increase in wild-type mice under the
high-sucrose feeding regimen that is absent in CrebH-null mice under the same
treatment (Figure 10). Moreover, CrebH-null and wild-type control mice were fed with
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the AHF diet for 6 months. The AHF diet (also called the Paigen diet) is known to
induce atherosclerosis and NAFLD in rodent models (91, 92). Similar to the fasting
and high-sucrose-diet-fed conditions, the liver of the CrebH-null mice expressed
significantly lower levels of the Fgf21 mRNA, compared to that of the wild-type control
mice, after AHF diet-feeding.

*

Figure 10. Quantitative real-time PCR results for high-sucrose and normal diet-fed
mice. Wild-type mice showed a statistically significant increase in Fgf21 expression
under high-sucrose diet that is not present in CrebH-null mice. High-sucrose diettreated wild-type mice showed no increase in CrebH expression. Fold changes of
mRNA expression levels were calculated after normalization to that of β-actin. Bars
denote mean values ± SEM (n=3). * p≤ 0.05.

High-fat diets have been shown to cause NAFLD and high sucrose diets are
known to induce insulin resistance (92, 93). In order to outline the physiological
effects of CREBH under dietary stress, I performed a glucose tolerance test (GTT)
and insulin tolerance test (ITT) on wild-type and CrebH-null mice under normal, highsucrose, and AHF diet-feeding conditions. Under the normal chow diet, CrebH-null
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and wild-type mice displayed similar patterns of blood glucose clearance in response
to exogenous glucose or insulin challenge (Figures 11 A and B). After feeding the
mice with AHF diet for six months, CrebH-null and wild-type mice still had similar
response patterns to infusion of exogenous glucose (Figure 11C). However, the
CrebH-null mice showed no response to insulin challenge during ITT (Figure 11D). It
is notable that CrebH-null mice displayed lower levels of blood glucose compared to
the wild-type control mice, which can be explained by the role of CREBH in
gluconeogenesis (Figure 11) (13). Surprisingly, when GTT was performed on mice
that were fed the high-sucrose diet, the CrebH-null mice were better able to clear
infused glucose than were wild-type mice (Figure 12A). This effect was quantified
using the incremental area under the curve method and found to be statistically
significant. To determine if this was due to insulin resistance that was present in wildtype mice and absent in CrebH-null mice, these mice were sacrificed and livers were
collected. Because AKT phosphorylation is a downstream effect of insulin signaling in
liver, the phosphorylation state of AKT was assessed by Western blot analysis
(Figure 12C). Corroborating the results of the GTT, high-sucrose fed CrebH-null mice
possessed higher levels of phosphorylated AKT, despite having somewhat lower
levels of total AKT.
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Figure 11. GTT and ITT analyses with CrebH-null and wild-type control mice after
normal or AHF diet. Fasted mice were infused with glucose or insulin via I.P.
injection. Blood glucose was measured before injection and at intervals during the 2hour recovery period. (A,B) GTT and ITT of mice after normal chow diet feeding.
(C,D) GTT and ITT of mice after AHF diet feeding. Bars denote mean values ± SEM
(n=3).
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Figure 12. Glucose tolerance test and
AKT phosphorylation in high-sucrose
diet-fed mice. (A-B) After high-sucrose
feeding, CrebH KO mice showed
increased ability in clearing blood
glucose in response to exogenous
glucose challenge compared to WT
mice. (C) KO mice showed higher
levels of AKT phosphorylation than
WT mice after high-sucrose feeding.
Bars denote mean values ± SEM
(n=8). * p≤ 0.05.
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Taken together, my studies suggested that CREBH regulates expression of
FGF21, a hepatic hormone that regulates whole-body energy metabolism, under the
metabolic stress conditions induced by fasting, the AHF diet, or the high-sucrose diet.
To confirm this regulation at the protein level, I examined serum levels of FGF21 in
the CrebH-null and wild-type control mice upon fasting or in the mice over-expressing
the activated form of CREBH or GFP control in livers. Upon 14 hours of fasting,
serum levels of FGF21 in the CrebH-null mice were significantly reduced, compared
to those of the control mice, as indicated by ELISA analysis (Figure 13A).
Furthermore, an activated form of CREBH or GFP control was over-expressed in
livers of wild-type control mice by using an adenoviral-based over-expression system.
Over-expression of the activated CREBH in mouse liver dramatically increased
serum levels of FGF21 in the mice after the fasting (Figure 13B), thus confirming the
role of CREBH in regulating FGF21 production from the liver.

Figure 13. CREBH activity increases FGF21 serum concentration. (A) CrebH KO
mice show decreased Fgf21 expression upon fasting. (B) Overexpression of CrebH
upregulates Fgf21 expression. Serum levels of FGF21 were determined by ELISA.
The bars denote mean values ± SEM (n=3). * p≤ 0.05; ** p≤ 0.01.
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2.4 Discussion
It has been documented that both CrebH and Fgf21 are upregulated by fasting
(76, 89). Although CREBH is known to play important roles in transcriptional
regulation of hepatic lipid metabolism, the regulatory targets of CREBH under
metabolic stress have only begun to be investigated. After identifying the key role that
CREBH plays in lipid and ketone regulation under AHF diet-induced metabolic stress,
a logical next step would be to characterize the role of CREBH in managing these
metabolites under fasting-induced metabolic stress. Our quantitative real-time PCR
analysis revealed fasting-induced targets of CREBH (Figure 8). One of these targets,
HMG-CoA synthase, is an enzyme responsible for production of HMG-CoA, an
upstream metabolite of both ketone body and cholesterol synthesis (94). This
corroborates the notable decrease in serum ketone body concentration (Figure 5).
Additionally, this provides an explanation for the previous finding that CrebH-null mice
present lower levels of cholesterol (total cholesterol, HDL, and LDL) (12).
The Ldha gene codes the M subunit of the LDH complex (95, 96). This subunit
entirely composes the LDH-5 complex, the isozyme present in liver tissue (95). This
enzyme converts lactic acid to pyruvate in the liver as part of the Cori cycle (97). The
resulting pyruvate then feeds in to gluconeogenesis pathway. The lower level of Ldha
in liver tissues of CrebH-null mice under fasting conditions could be a contributing
factor to the low blood glucose level seen in these animal models (Figure 8) (12, 13).
The Ldha fasting expression pattern shows a steady increase as fasting length
increases in wild-type mice (Figure 11). This increase is not present in the CrebH-null
mice, which maintains a similar expression level at all time points. This pattern
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indicates a third regulation pattern that consistently increases over the course of the
fast and is entirely dependent on CREBH activity. The fact that the CrebH-null mice
maintain a steady level of Ldha expression that is similar to that of wild-type mice
under the feeding condition shows that CREBH is not necessary to maintain the base
line level of Ldha expression.
Bdh1 is an enzyme involved in ketogenesis that was previously shown to be
regulated by CREBH (11, 98). The fasting-induced expression profile of Bdh1 shows
that wild-type mice have peak expression during the 12- and 24-hour fasting periods
(Figure 11). These longer fasting periods represent time points when ketogenesis
would become active. The CrebH-null mice do not show increased expression during
these periods. This shows the necessity of CREBH in Bdh1 induction upon fasting
and indicates the importance of CREBH in ketogenesis.
Apolipoproteins are proteins involved in lipid transport and lipolysis (99). Two
apolipoproteins, ApoA5 and ApoC2, were down-regulated in fasting CrebH-null mice
compared to fasting wild-type mice (Figure 10). These two genes have previously
been shown to be regulated by CREBH under a high-fat diet (12). ApoA5 is involved
in the formation of lipid-carrying lipoprotein particles, such as HDL and VLDL (100).
ApoC2 facilitates the interaction between lipoprotein particles and lipoprotein lipase
(101). This interaction is important for delivery of the TG to peripheral tissues.
Because apolipoproteins are core components of lipid-carrying particles, they are
essential to lipid clearance in blood, and human polymorphisms in these genes are
linked to hyperlipidemia (102). Our previous studies have shown that CrebH-null mice
demonstrate hyperlipidemia when fed an AHF diet (12). I have demonstrated that
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hyperlipidemia occurs in CrebH-null mice under fasting conditions, as well (Figure 5).
The hyperlipidemia phenotype is likely due to down-regulation of ApoC2 and ApoA5
in CrebH-null mice. Additionally, owing to the importance of these proteins in delivery
of lipids to peripheral tissues, the absence of ApoC2 and ApoA5 in CrebH-null mice
may be responsible for the small fat pads present in these mice under the AHF diet
compared to wild-type mice under the same diet (12).
A critical gene regulated by CREBH under fasting is Fgf21 (Figure 8).
Previously, through microarray gene expression analysis, we identified several
groups of CREBH-regulated genes that are involved in lipolysis, FA oxidation, and
lipogenesis (12). However, how CREBH modulates perplex genetic programs
involved in multiple lipid metabolic pathways remains to be elucidated. FGF21 is a
fasting-induced hormone responsible for activating multiple metabolic stress
response pathways (76). FGF21 exerts pleiotropic effects on hepatic FA oxidation,
ketogenesis, and lipolysis by reprogramming gene transcription in lipid metabolism in
the liver upon fasting or under a methionine- and choline-deficient (MCD) diet (76,
103, 104). Identifying Fgf21 as a target of CREBH may explain the role of CREBH in
lipid metabolism during states of metabolic stress. Fgf21 displays an interesting
expression pattern upon fasting (Figure 9). In wild-type mice, Fgf21 expression peaks
during the 6- and 12-hour fast, but begins to lower during the 24-hour fast. This
pattern is the same in CrebH-null mice, but the relative mRNA levels are
approximately 10-fold lower. In this case, another factor seems to be regulating the
pattern of expression based on the length of the fast, but CREBH appears to be
upregulated FGF21 during all of the fasting periods studied. Fgf21 has also been
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shown to be up-regulated by dietary sucrose ingestion (90). Our own high-sucrose
diet experiments corroborate this observation (Figure 10). However, Fgf21 mRNA
levels are not increased in CrebH-null mice under high-sucrose diet. This implies that
sucrose-dependent Fgf21 mRNA level increases are mediated by CREBH.
Interestingly, mRNA levels of CrebH are not affected by the high-sucrose diet. This is
similar to the CrebH mRNA level observed in mice under the AHF diet, which also
showed an increase in Fgf21 mRNA levels. A distinction between the high-sucrose
and the AHF diets, though, is the lack of increased expression of Pparα mRNA in
high-sucrose diet-fed mice (105). The link established between FGF21 and CREBH
in these experiments led us to investigate the relationship between these two proteins
and possible role of FGF21 as a mediator of CREBH.
Previous studies have shown that CrebH mediates different metabolic
processes depending on the type of stress endured by the hepatocyte (9, 12, 13, 89).
Some of the processes that CrebH regulates are even in opposition to each other
(e.g. lipolysis under AHF-feeding and lipogenesis under ER stress). We hypothesized
that CREBH may initiate different fasting-induced pathways based on the length of
the fasting stress. We designed an experiment to test the effect of various fasting
conditions on CREBH target gene expression. If CREBH does differ in its regulatory
targets based on different fasting conditions, we should expect to see CREBH targets
displaying different expression profiles for individual genes. Indeed, multiple profiles
were identified, confirming this hypothesis (Figure 9). However, CrebH itself shows
only a modest increase in expression due to fasting. This may be misleading, though,
as CREBH activity cannot be accurately expressed by its mRNA level. CREBH
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activity is also regulated at the protein level by RIP-mediated cleavage (Figure 4).
Additionally, as we will demonstrate in the following chapter, a binding partner can
modify the transcriptional activity of CREBH.
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CHAPTER III: CREBH Works in Concert with PPARα to Regulate
Fgf21 Expression
3.1 Summary
In the previous chapter, the regulatory relationship between CREBH and Fgf21
was established. In this chapter, we define the mechanism by which CREBH
regulates Fgf21 expression. Analysis of the Fgf21 gene promoter identified highlyconserved CRE and PPRE1/2 response elements in close juxtaposition, indicating
protein-DNA binding sites for CREBH and PPARα. DNA binding of CREBH and
PPARα was confirmed by ChIP analysis. Site-mutation was performed to generate
mutant FGF21 promoter regions, representing mutations in each of newly discovered
response elements, for luciferase reporter assay. Reporter assay indicated that the
CRE and PPRE2 are vital to CREBH- and PPARα-mediated Fgf21 expression.
CREBH and PPARα act in synergy to induce expression of the Fgf21 gene promoter.
Moreover, the proximity of the binding sites suggested a possible protein-protein
interaction between CREBH and PPARα. This discovery of the possible interaction
was followed by verification of the interaction and investigation of its importance. IPWestern blotting analysis showed that CREBH and PPARα interact under fastingand AHF diet-induced stress. CREBH and PPARα were shown to be necessary for
proper expression of Fgf21 during fasting-induced metabolic stress. Our study found
that CREBH and PPARα regulate each other transcriptionally and interact with each
other to induce Fgf21 transcription.
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3.2 Materials and Methods
Materials
Chemicals were purchased from Sigma unless indicated otherwise. Synthetic
oligonucleotides were purchased from Integrated DNA Technologies, Inc. (Coralville,
IA). Antibodies against flag and β-actin were purchased from Sigma. Mouse
monoclonal anti-PPARα antibody was purchased from Millipore (Billerica, MA),
Mouse monoclonal anti-FGF21 antibody and FGF21 ELISA kit were purchased from
R & D Systems, Inc. (Minneapolis, MN). Polyclonal anti-CREBH antibody used for
Western blot analysis was raised in our laboratory as previously described (106). Kits
for measuring TG and FA were from BioAssay Systems (Hayward, CA).
Mouse experiments
The CrebH-null mice were previously generated as described (8). The Pparαnull mice were purchased from the Jackson Laboratories. The CrebH-null, Pparα-null,
and wild-type control mice on a C57Bl/6J background at approximately 3-month-old
were used for the experiments. All the animal experiments were approved by the
Wayne State University IACUC committee and carried out under the institutional
guidelines for ethical animal use.
Cell culture experiments
The hepatocarcinoma cell line Huh-7 was kindly provided by Dr. Charles Rice
at the Rockefeller University [1]. Huh-7 cells were plated on 10-cm plates and
maintained in DMEM/High Glucose media containing 100 units/ml penicillin, 100
μg/ml streptomycin, and 10% fetal bovine serum. The cells at about 60% confluence
were infected with adenovirus-expressing GFP (Ade-GFP), adenovirus-expressing
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CREBH (Ade-CREBH), adenovirus-expressing PPARα (Ade-PPARα), or combination
of Ade-CREBH plus Ade-PPARα at an MOI of 100 for 48 hours before they were
collected for ChIP analyses.
ChIP assay
The Huh-7 cells were infected with equal amounts of Ade-GFP, Ade-CREBH,
Ade-PPARα, or combination of Ade-CREBH and Ade-PPARα. To determine the
binding of CREBH and/or PPARα to the FGF21 promoter region, we used a
commercial ChIP assay kit (Millipore, MA) according to the manufacturer’s instruction
with modifications as previously reported (106). A polyclonal anti-CREBH antibody or
a monoclonal anti-PPARα antibody (Millipore, MA) was used for IP. The genomic
DNA controls isolated from sonicated cell lysates and immunoprecipitated DNAs
were both extracted with the chelex-100 kit (Bio-Rad, CA). For the cross-link
procedure, formaldehyde was added directly to the medium to a final concentration of
1%. The cultures were incubated for 10 min at 37 ˚C. Cells were washed with ice-cold
PBS containing protease inhibitors and collected by centrifugation. Cell pellets were
re-suspended in 200 μl SDS lysis buffer, and were sonicated to obtain DNA
fragments of 200-1000 bp. For the PCR analysis, 1 μl DNA sample was mixed with 5
μM human FGF21 forward primer (5’-ATTCAGGCTGCCCTTGCCACG-3’), 5 μM
human FGF21 reverse primer (5’-GCCTGGCTCCTCTTTCGGC-3’), and 18 μl PCR
supermix. As a control, PCR reaction was 3 carried out with the control primers
(forward;

5’

CACCAGGGTCTCCGATCTCCCA-3

TGCTGGAGGTGGGCCTTGGAC-3’).

and

reverse;

5’-
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Quantitative Real-time RT-PCR
For real-time PCR analysis, the reaction mixture containing cDNA template,
primers, and SYBR Green PCR Master Mix (Applied Biosystems) was run in a 7500
Fast Real-time PCR System (Applied Biosystems, Carlsbad, CA). Fold changes of
mRNA levels were determined after normalization to internal control β-actin mRNA
levels. The primer sequences are described in Appendix A.
Western Blot analysis
Total cell lysates were prepared from either liver tissue or cultured cells using
NP-40 lysis buffer (1% NP-40, 50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.05% SDS,
0.5 mM Na vanadate, 100 mM NaF, 50 mM β-glycerophosphate, and 1 mM
phenylmethylsulfonyl fluoride) supplemented with protease inhibitors (EDTA-free
Complete Mini, Roche) as previously described (107). Denatured proteins were
separated by SDS-PAGE on 10% Tris-glycine polyacrylamide gels and transferred to
a 0.45-mm PVDF membrane (GE Healthcare) followed by Western blot analysis with
anti-CREBH, anti-PPARα, anti-FGF21, or anti-β actin antibody. Membrane-bound
antibodies were detected by chemiluminescence detection reagents (GE Healthcare).
Immunoprecipitation (IP) – Western blot analysis
The interaction between CREBH and PPARα was determined by IP-Western
blot assay. For preparation of the whole lysates, liver tissues were homogenized and
lysed with Nonidet P-40 lysis buffer containing protease inhibitor cocktail as
previously described (107). For IP, 200 μg of the whole lysate were incubated with 3
μg of specific protein antibody for overnight at 4°C. Immunoprecipitated proteins were
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resolved by SDS-PAGE followed by immunoblotting using an anti-CREBH or antiPPARα antibody.
Site-directed mutagenesis
Site mutation was introduced into the CREB-PPRE binding motif in the FGF21
gene promoter using the QuickChange II Site-directed Mutagenesis Kit (Stratagene)
according to manufacturer’s instruction. All the constructed plasmid vectors were
confirmed by DNA sequencing. All the reporter assays were performed in triplicate.
The

primers

used

for

site-directed

CAAATATCACGCCACAGGAGTGGG-3’;

mutagenesis

are:

and

5’5’-

CCCACTCCTGTGGCGTGATATTTG-3’.
Luciferase reporter analysis
For luciferase reporter analysis, we used Dual-Luciferase Reporter Assay
System (Promega). Hepa1-6 cells were co-transfected with the reporter vectors and
control reporter vector pGL4.7 and infected with adenovirus Ade-GFP, Ade-CREBH,
Ade-PPARα, or Ade-CREBH plus Ade-PPARα. Luciferase assay was performed at
48 hours after transfection/infection. Data graphs were presented after normalization
of Firefly luciferase reporter activities to the control Renilla luciferase activities.
Statistics
Experimental results are shown as mean ± SEM (for variation between
animals or experiments). All in vitro experiments were repeated with biological
triplicates at least three times independently. Mean values for biochemical data from
the experimental groups were compared by paired or unpaired, 2-tailed Student’s t
tests. Multiple comparisons were compared with ANOVA and proceeded by ad hoc
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statistical test when necessary. Statistical tests with P < 0.05 were considered
significant.
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3.3 Results
After establishing the regulatory effect of CREBH on Fgf21 expression, our
next step was to delineate the mechanism of this effect. Analysis of the Fgf21 gene
revealed a highly-conserved cAMP response element (CRE) within the promoter
region, 63 nucleotides upstream from the transcription start site (Figure 14). This site
serves as a binding region for CREB protein family members, including CREBH, to
initiate transcription (10, 108). Upstream from this element, in close proximity, is an
also highly conserved PPAR response element (PPRE), which serves a binding
region for PPAR proteins (109). The PPRE is composed of two individual binding
elements, PPRE1 and PPRE2. The proximity of the binding sites suggests a possible
interaction between CREBH and a PPAR protein.

Figure 14. Inspection of conserved Fgf21 gene promoter region elements across
mammalian species. cAMP response element (CRE) and PPAR response elements 1
and 2 (PPRE-1 and PPRE-2) are highly conserved and in close proximity within the
Fgf21 promoter region.

In order to determine the contribution of the CRE, PPRE1, and PPRE2 binding
elements in CREBH- and/or PPARα-mediated Fgf21 expression, we performed site
directed mutagenesis for each of these regions (Figure 15). This process was used to
produce four mutant forms of the Fgf21 promoter region. The FM13 mutant contained
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an AC to TG conversion in the CRE element. The PE-M1 mutant contained an AT to
CG conversion in the PPRE1 element. The PE-M2 mutant contained an AC to CG
conversion in the PPRE2 element. The fourth mutant promoter region, PE-M12,
contained both mutations present in the PE-M1 and PE-M2 mutants. The mutant
promoter regions were fused to luciferase reporter genes (Figure 15A). The resulting
plasmids were used to transfect Hepa1-6 cells. Reporter assays were performed after
infection of the Hepa1-6 cells with adenovirus expressing GFP, CREB, CREBH, or
PPARα (Figures 16 and 17). CrebH and PPARα overexpression were verified by
Western blot analyses (Figure 18). CrebH overexpression was also verified by
measurement of serum and hepatic TG (Figure 19). Exogenous expression of CREB
showed no increase in reporter activity from the wild-type, PE-M1 or PE-M2
promoters (Figure 16B). The wild-type, PE-M1, and PE-M2 promoters showed
reporter activity under exogenous CrebH expression, however. Reporter activity from
the PE-M2 promoter was slightly lower than from the wild-type and PE-M1 promoters
under this condition. Exogenous expression of CrebH showed no reporter activity
with the FM13 promoter (Figure 17A). The wild-type, PE-M1, and PE-M2 promoters
showed reporter activity under co-overexpression of CrebH and GFP (Figure 17C).
Reporter activities from the PE-M2 and PE-M12 promoters were slightly lower than
from the wild-type and PE-M1 promoters under this condition, as well. Cooverexpression of CrebH and GFP showed no reporter activity with the FM13
promoter (Figure 17B). Co-overexpression of PPARα and GFP induced reporter
activity of the PE-M1, PE-M2, PE-M12, and wild-type promoters; PE-M2 and PE-M12
showed lower activity than PE-M1 and wild-type (Figure 17C). This condition showed
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no reporter activity from the FM13 promoter (Figure 17B). Co-overexpression of
CrebH and PPARα-induced the highest reporter activity in the wild-type, PE-M1, PEM2, and PE-M12 promoters (Figure 17C), suggesting a synergy of CREBH and
PPARα in driving Fgf21 expression. This condition did not induce reporter activity
with the FM13 promoter (Figure 17B).

Figure 15. Site-directed mutagenesis of the human FGF21 gene promoter. WT, CREmutated (FM13), PPRE1-mutated (PE-M1), and PPRE2-mutated (PE-M2) forms of
the FGF21 promoter region. A fourth mutant that contained the mutations present in
PE-M1 and PE-M2, called PE-M12, was also created.
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Figure 16. Description of luciferase reporter assay. (A) Illustration of luciferase fused
to WT and mutant promoter regions. (B) Reporter assay demonstrating the specificity
of CREB binding in the Fgf21 promoter region. Hepa 1-6 cells were transduced with
the WT or mutant form of the Fgf21 promoter fused to the luciferase promoter gene.
Cells were transfected with a control plasmid, plasmid expressing CREB, or plasmid
expressing CREBH. The bars denote mean values ± SEM (n=3 biological repeats). **
p≤ 0.01.
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Figure 17. Reporter assay for the mutated Fgf21 promoter region. (A-C) Hepa 1-6
cells were transiently transduced with expression vectors containing the WT or
mutated Fgf21 promoter region linked to a luciferase reporter. (A) Cells expressing
WT or FM1 linked reporter gene were infected with adenovirus expressing active
CrebH. (B) Cells with WT or FM1 linked reporter gene were infected with adenovirus
expressing active combinations of CrebH, Pparα, and GFP. (C) Cells with WT, PEM1, PE-M2, or PE-M12 linked reporter gene were infected with adenovirus
expressing active CrebH, Pparα, and GFP. The bars denote mean values ± SEM
(n=3 biological repeats). * p≤ 0.05; ** p≤ 0.01.

49

Figure 18. Western blot analysis to validate adenoviral overexpression of CrebH and
PPARα in CrebH- or Pparα-null mice. (A) Hepatic CREBH content in Pparα-null mice
overexpressing CrebH or GFP. (B) Hepatic PPARα content in CrebH-null mice
overexpressing PPARα or GFP.

Figure 19. Verification of CrebHexpressing adenovirus using
measurements of (A) serum TG,
(B) hepatic TG, and (C) body
weight in male wild-type mice
after four months of AHF feeding.
The bars denote mean values ±
SEM (n=3 for GFP expressing
mice and 4 for CREBHexpressing mice). ** p≤ 0.01.
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Real-time PCR analysis of CrebH-null and wild-type mice after a 14-hour
overnight fast was performed and this analysis revealed targets of CREBH
transcriptional regulation. Both CrebH and Fgf21 mRNA levels were upregulated in
response to fasting in wild-type mice. This pattern is not observed in CrebH-null mice.
Similar pattern is observed in PPARα mRNA levels (Figure 20). Real-time PCR for
these genes was performed on Pparα-null mice and wild-type counterparts under
fasting conditions. The expression profile of CrebH in Pparα-null mice resembled that
of Pparα in CrebH-null mice. The mRNA levels of these genes are reflected in the
levels of associated proteins in the null mouse models (Figure 21). Together, these
data suggest a reciprocal regulation between CREBH and PPARα (i.e. CREBH and
PPARα regulate each other for their induction upon fasting).

Figure 20. Quantitative real-time PCR analysis of CrebH-null, Pparα-null, and wildtype control mice under fed and fasting conditions. (A) CrebH, Fgf21, and Pparα
mRNA levels in CrebH-null and wild-type mice. (B) CrebH, Fgf21, and Pparα mRNA
levels in Pparα-null and wild-type mice. Fold changes of mRNA expression levels
were calculated after normalization to that of β-actin. Bars denote mean values ±
SEM (n=3). * p≤ 0.05; ** p≤0.01.
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Figure 21. Western blot analysis of null mice under fed and fasting conditions. (A)
CrebH, Fgf21, and Pparα protein levels in CrebH-null mice. (B) CrebH, Fgf21, and
Pparα protein levels in Pparα-null mice. Results compared to β-actin expression.
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In order to determine the individual contribution of PPARα and CREBH to the
hepatic expression of Fgf21, an adenoviral rescue experiment was performed. Pparαnull and CrebH-null mice were fasted and injected with CrebH- or Pparα-expressing
adenovirus, respectively. These rescue-treated mice were compared to wild-type and
untreated null mice under fed and fasting conditions. Liver and blood serum were
collected. Real-time PCR was performed on liver tissue (Figure 22). Wild-type, fed
mice showed a low, baseline level of Fgf21 mRNA expression, which was severalfold lower than the expression level of wild-type mice under the fasting condition. This
baseline level was matched in Pparα-null and CrebH-null mice under both fasting and
feeding conditions. Fasted CrebH-null and Pparα-null mice that were injected with
GFP-expressing adenovirus displayed baseline or lower than baseline levels of Fgf21
expression. Pparα-null mice that overexpressed CrebH showed a significant increase
in Fgf21 expression levels, compared to the fed, Pparα-null mice. However, these
mice showed lower levels of Fgf21 expression than the wild-type, fasted mice.
CrebH-null mice that overexpressed Pparα displayed only a baseline expression level
of Fgf21 mRNA. Western blot analysis showed that serum FGF21 protein levels
varied slightly from hepatic Fgf21 mRNA levels (Figure 23). Serum FGF21 protein
levels were low or undetectable in wild-type mice under the fed condition. Fasted,
wild-type mice had observably higher FGF21 serum levels than fed, wild-type mice.
Serum FGF21 levels of CrebH-overexpressing, fasted Pparα-null mice were similar to
those from the fasted wild-type mice. Serum FGF21 levels of fasted CrebH-null mice
over-expressing Pparα were detectable, but notably lower than wild-type, fasted
levels.
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Figure 22. Quantitative real-time PCR analysis of hepatic Fgf21 mRNA levels in
CrebH-null, Pparα-null, and wild-type control mice under fed and fasting conditions
with and without adenoviral rescue procedure. (A) Fgf21 levels in WT and Pparα-null
mice under fed and fasting conditions. Additional Pparα-null mice were treated with
adenovirus expressing GFP or CrebH, and Fgf21 mRNA levels were assessed. (B)
Fgf21 levels in WT and CrebH-null mice under fed and fasting conditions. Additional
CrebH-null mice were treated with adenovirus expressing GFP or Pparα, and Fgf21
mRNA levels were assessed. Fold changes of mRNA expression levels were
calculated after normalization to that of β-actin. Bars denote mean values ± SEM
(n=3). * p≤ 0.05; p ≤ 0.01.
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Figure 23. Western Blot analysis of serum FGF21 protein levels in CrebH- and
Pparα-null mice under fed or fasting conditions with and without adenoviral rescue
procedure. (A) FGF21 protein levels in WT and Pparα-null mice under fed and fasting
conditions. Additional Pparα-null mice were treated with adenovirus expressing GFP
or CrebH, and FGF21 protein levels were assessed by Western blot analysis. (B)
FGF21 protein levels in WT and CrebH-null mice under fed and fasting conditions.
Additional CrebH-null mice were treated with adenovirus expressing GFP or Pparα,
and FGF21 protein levels were assessed. Serum albumin protein levels were
determined as loading controls.
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The capability of PPARα and CREBH to bind to the promoter region of the
Fgf21 gene was determined in order to evaluate the proteins as possible initiators of
Fgf21 gene transcription. DNA-protein binding was activity assessed via ChIP assay
(Figure 24A). Huh7 cells were infected with adenovirus-expressing GFP, active
CrebH, Pparα, or a combination of active CrebH and Pparα. PCR was performed on
the precipitate product using primers targeting the Fgf21 gene promoter region
(Appendix B). Protein-DNA binding complexes in Huh7 cells expressing CrebH,
Pparα or a combination of the two were pulled-down using anti-PPARα or antiCREBH antibodies and subjected to ChIP-PCR amplification of the Fgf21 gene
promoter region containing the CRE-PPRE binding elements (Appendix B). The
ChIP-PCR results showed that CREBH and PPARα can bind to the Fgf21 gene
promoter (Figure 24A). Interestingly, co-expression of CREBH and PPARα yielded
stronger binding activity to the Fgf21 promoter than expression of either CREBH or
PPARα, thus confirming the synergistic effect of CREBH and PPARα on driving
Fgf21 gene transcription. As a control, expression of GFP yielded negative results
with PPARα and CREBH pull-down.
Because the cAMP response element is a binding site for multiple members of
the CREB protein family, we tested the specificity of the element for CREBH binding
via ChIP assay (Figure 24B). Huh7 cells were infected with plasmid expressing Creb1
or CrebH or an empty vector. Pull-down was performed with cells over-expressing
Creb1 or vector control using anti-CREB and anti-CREBH antibodies. PCR was used
to amplify the same Fgf21 promoter sequence as the previous experiment. Pull-down
using anti-CREB antibodies failed to produce positive Fgf21 promoter-binding signals
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(Figure 24B), suggesting that it is CREBH, not CREB, that binds to the proximal
Fgf21 gene promoter.

Figure 24. ChIP assay for CREBH, PPARα, and CREB binding activities at the
human FGF21 gene promoter region. (A) ChIP with Huh7 cells infected with
adenovirus expressing GFP CrebH, Pparα, or an equal-titer combination of CrebH
and Pparα. PCR was used to amplify the target sequence on the Fgf21 promoter
region containing the CRE-PPRE consensus sequence (Appendix B). Input used as
positive control. Negative controls include the Huh7 cells with GFP overexpression,
no antibody pull-down, IgG antibody pull-down, and PCR using primers targeting the
FUT1 gene. (B) ChIP using Huh7 cells transfected with plasmid expressing CREB or
CREBH or empty vector. PCR was used to amplify the target sequence on the Fgf21
promoter region. Input used as positive control. Negative controls include empty
vector transfection, no antibody pull-down, IgG antibody pull-down, and PCR using
primers targeting the FUT1 gene. An additional positive control was included for
CREB-transfected cells. In this control, PCR was performed using primers targeting
the promoter region of the known CREB target, Pck1.
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To identify interactions between CREBH and PPARα immunoprecipitation (IP)
Western blotting analyses were performed with liver tissue samples from mice under
fasting or after AHF diet feeding (Figure 25). Liver tissues from wild-type mice under
normal chow feeding, 14-hour overnight fasting, or after 6-month AHF diet feeding
were homogenized and protein was isolated. Pull-down was performed with the antiCREBH or anti-PPARα antibody. Pull-down fraction and whole lysate were analyzed
by Western blot and probed with the anti-CREBH or anti-PPARα antibody. Western
blot showed the interaction between PPARα and CREBH that is particularly favored
under the fasting or AHF diet-fed condition.

Figure 25. Immunoprecipation of liver protein lysates from wild-type mice under
metabolic stress. Liver lysate from wild-type mice under normal chow, fasting, or AHF
diet feeding. Precipitation was induced by pull-down with the anti-PPARα or antiCREBH antibody. Pull-down fractions and whole lysate were probed with the PPARα
or CREBH antibody. Levels of β-actin in the total lysates were determined as loading
controls.
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3.4 Discussion
Owing to the potential of Fgf21 as a key component of CREBH metabolic
control, we sought to define the relationship underlying this regulation and its
mechanism. This resulted in the discovery of the conserved and adjacent CRE and
PPRE-1/2 elements on the promoter region of the Fgf21 gene (figure 14). The
conserved nature of the elements marks them as potentially integral for proper
expression of Fgf21. The proximity of these elements indicates that a PPAR protein
family member may be functioning as a binding partner for CREBH during Fgf21
induction. A previous study had revealed that, under an AHF-diet, CREBH upregulates Pparα expression. Figures 20 and 21 showed the shared regulatory pattern
of CrebH- and Pparα-null mice under feeding and fasting conditions. These analyses
also identify PPARα as a mediator of fasting-induced Fgf21 up-regulation.
In order to determine the importance of the CRE and PPRE1/2 elements in
Fgf21 expression, we carried out a reporter assay using the wild-type Fgf21 gene
promoter and its mutant isoforms (FM13, PE-M1, PE-M2, and PE-M12). The FM
promoter with the site mutation in the CRE binding element was unable to produce
reporter activity under CREBH overexpression conditions (Figure 17). This shows the
importance of the CRE element. Indirectly, this indicates that Fgf21 expression is
highly dependent on CREBH. The reporter activity linked to the PE-M1 promoter with
the site mutation in one of the PPRE binding elements in the Fgf21 gene promoter
was similar to that of the wild-type promoter in all testing conditions (Figures 16 and
17). Additionally, reporter activities driven by the PE-M2, which harbors a site
mutation at the second PPRE binding element in the Fgf21 gene promoter, and PE-
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M12, in which both PPRE elements were mutated, were similar in all overexpression
conditions and both were lower than that of the wild-type promoter. This leads us to
the conclusion that PPRE1 does not play a role in CREBH- or PPARα-dependent
Fgf21 upregulation, but PPRE2 does play a role in this regulation. Due to the higher
level of reporter activity in cells that co-expressed Pparα and CrebH, compared to
expression of Pparα or CrebH alone, it is clear that both proteins are required to
reach proper levels of Fgf21 expression.
The next step of our study was to determine the individual contributions of
CREBH and PPARα as inducers of Fgf21. We attempted to rescue Fgf21 expression
in both CrebH- and Pparα-null mice with Pparα and CrebH overexpression,
respectively (Figures 22 & 23). The results of this experiment showed that, while both
PPARα and CREBH play a role in the regulation of Fgf21, exogenous expression of
CREBH alone is sufficient to induce Fgf21 transcription, but PPARα requires
interaction with CrebH to accomplish the same result.
In Figure 25, we showed that inducing metabolic stress by fasting or AHF diet
results in interaction between CREBH and PPARα. This indicates the existence of a
CREBH-PPARα complex under metabolic stress. By employing ChIP analyses, we
were able to show direct binding of the CREBH-PPARα complex to the Fgf21
promoter (Figure 24). We were also able to show that the CRE binding site on the
promoter is specific to CREBH. This leads us to conclude that PPARα interacts and
forms a complex with CREBH under metabolic stress, such as fasting or AHF dietfeeding. This complex binds to the CRE and PPRE1/2 elements of the Fgf21
promoter region and initiates Fgf21 transcription. The transcriptional upregulation
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results in increased FGF21 protein content in mouse liver and serum under fasting
conditions (Figures 13 and 20).
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CHAPTER IV: Exogenous FGF21 Administration Rescues CrebHnull Phenotype
4.1 Summary
CrebH-null mice are susceptible to AHF diet-induced NAFLD and NASH.
FGF21, a transcriptional target of CREBH, has proven to be a potent treatment option
for these diseases. In this chapter, we describe the rescue of the NASH phenotype of
CrebH-null mice developed under the AHF diet by injections of recombinant human
FGF21 protein. Treatment with recombinant protein was an effective method of
increasing serum FGF21 protein levels and decreasing body weight in CrebH-null
mice when compared to vehicle control. Injection of FGF21 improved hyperlipidemia,
hypoketonemia, hepatic steatosis, hepatocyte ballooning, and hepatomegaly.
Additionally, glucose tolerance was improved in AHF diet-fed CrebH-null mice upon
FGF21 protein treatment. The success of this treatment in rescuing the AHF diet-fed
CrebH-null mouse disease phenotype indicates the importance of FGF21 in the
CREBH-regulated metabolic stress response. Furthermore, effectiveness of the
treatment puts FGF21 forward as a potential exciting therapeutic option for
hypertriglyceridemia and NASH.
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4.2 Materials and Methods
Materials
Synthetic

oligonucleotides

were

purchased

from

Integrated

DNA

Technologies, Inc. (Coralville, IA). The crude blood serum antibody was purified
through affinity purification. Kits for measuring TG, FA, and ketone body 3hydroxybutyric acid were from BioAssay Systems (Hayward, CA). Purified, bioactive
recombinant human FGF21 protein was purchased from ProSpec-Tany TechnoGene
Ltd (Ness Ziona, Israel). Mouse monoclonal anti-FGF21 antibody and FGF21 ELISA
kit were from R & D Systems, Inc. (Minneapolis, MN). OneTouch Ultra glucometer
and blood glucose measurement strips were purchase form Johnson & Johnson, Inc.
Animal experiments
For the FGF21 rescue animal experiment, daily injections of purified, bioactive
rhFGF21 protein and control injections of vehicle (sterile water) were carried out for 8
days. CrebH-null and wild-type control male mice after the AHF diet for 6 months
were injected i.p. with 0.1 g purified recombinant human FGF21 protein per gram
body weight or the vehicle PBS. On the fifth day of injection, mice were fasted for 12
hours. Following fasting, on the sixth day of injection, glucose tolerance tests were
performed. Mice were allowed to recover for 2 days with ongoing injections before
they were euthanized and tissues were harvested. All the animal experiments were
approved by the Wayne State University IACUC committee and carried out under the
institutional guidelines for ethical animal use.
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Measurement of mouse lipid metabolites
Liver tissue and blood plasma samples were isolated from the mice under the
normal chow diet, after fasting, or after the AHF diet. To determine hepatic TG levels,
approximately 100 mg liver tissue was homogenized in 500 μl PBS followed by
centrifugation at 10K r.p.m for 5 min. The supernatant was mixed with 500 μl 10%
Triton-100 in PBS for TG measurement using a commercial kit (BioAssay Systems,
CA). Mouse hepatic TG levels were determined by normalization to liver tissue mass
used for TG measurement. Mouse blood plasma samples were subjected to
quantitative analyses of TG, free FA, and the ketone body metabolite 3hydroxybutyric acid using the commercial kits (BioAssay Systems).
Oil-red O staining
Frozen liver tissue sections were stained with Oil-red O for lipid contents
according to standard protocol (107). Briefly, frozen liver tissue sections of 8 microns
were air-dried, and then fixed in formalin. The fixed sections were rinsed with 60%
isopropanol before they were stained with freshly prepared Oil-red O solution for 15
minutes. After Oil-red O staining, liver sections were rinsed again with 60% isopropanol
followed by washing with water before subjected to microscope analysis.
Sirius-red staining of hepatic collagens
Sirius-red staining of collagen deposition in liver tissue section for fibrosis
evaluation was as previously described (107). Briefly, paraffin-embedded mouse liver
tissue sections (5μm) were pretreated with xylene, ethanol, and water according to
the standard protocol. The liver tissue sections were stained for 1 hr with Sirius red
solution (Sigma) and then washed with acidified water (0.5% acetic acid). The stained
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tissue sections were dehydrated with 100% ethanol and cleared in xylene before
being mounted with mounting solution.
GTT assay
Glucose tolerance tests of the CrebH-null and wild-type control mice after 6
days of administration of the FGF21 protein or vehicle. Animals were fasted for 12
hours before infused with 1 mg D-glucose per gram body weight. Blood glucose
levels were measured from tail blood using an OneTouch Ultra glucometer (Johnson
& Johnson).
Statistics
Experimental results are shown as mean ± SEM (for variation between
animals or experiments). All in vitro experiments were repeated with biological
triplicates at least three times independently. Mean values for biochemical data from
the experimental groups were compared by paired or unpaired, 2-tailed Student’s t
tests. Multiple comparisons were compared with ANOVA and proceeded by ad hoc
statistical test when necessary. Statistical tests with P < 0.05 were considered
significant.
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4.3 Results
In order to determine whether Fgf21 is the major target of CREBH in regulating
lipid metabolism and to evaluate the potential effect of FGF21 on reversing the NASH
phenotype resulting from CrebH deletion, we fed the AHF diet to CrebH-null mice to
establish the NASH disease model.

Figure 26. Effects of administration of recombinant FGF21 protein on serum FGF21
levels and body weights. (A) CrebH-null mice showed increased circulating levels of
FGF21 upon FGF21 protein administration. (B) FGF21 protein administration induced
a modest but significant decrease in body weight compared to the vehicle control.
Each bar denotes the mean ± SEM (n=5 mice treated with vehicle and 4 mice treated
with FGF21). * P≤0.05.
We administered a series of recombinant human FGF21 protein injections to
CrebH-null mice after the AHF diet. FGF21 protein was administered by
intraperitoneal injection daily for 8 days. Effectiveness of FGF21 protein
administration was assessed by FGF21 serum concentration after the series of
injections in CrebH-null mice (Figure 26). FGF21 protein administration successfully
increased circulating FGF21 protein levels. Additionally, since long term FGF21
protein administration has been shown to induce weight loss in mice, mouse body
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weight was measured upon the 8-day administration of FGF21 protein (82, 84).
Protein injection was accompanied by small but significant decrease in body weight
for the FGF21-injected mice (Figure 26).

Figure 27. Infusion of recombinant FGF21 protein reverses hypertriglyceridemia, and
hypoketonemia in CrebH-null mice after the AHF diet. CrebH-null (KO) and wild-type
(WT) control mice were fed with AHF diet for 6 months before they were injected i.p.
with purified recombinant FGF21protein or vehicle once a day for 8 days. Levels of
serum TG (A), ketone body BOH (B), and FA (C) in the WT and CrebH-null mice
administrated with recombinant FGF21 protein or vehicle (Veh). The blood samples
were collected from the mice after 12-hour fasting on the sixth day of administration
of FGF21 protein or vehicle. Each bar denotes the mean ± SEM (n = 5 WT or KO
mice treated with vehicle and 4 KO mice treated with FGF21). *, p ≤ .05; **, P ≤ 0.01.

To determine the ability of FGF21 to rescue metabolic syndrome in AHF dietfed CrebH-null mice, wild-type and CrebH-null mice were fed an AHF-diet for 6
months. After the feeding period, CrebH-null mice were administered either FGF21
protein or vehicle control (PBS). Wild-type mice were given vehicle control only.
CrebH-null mice that received FGF21 injection showed improved lipid metabolite
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profiles and liver pathological states compared to vehicle-injected CrebH-null mice
controls (Figure 27). Vehicle-injected control CrebH-null mice exhibit increased TG
and free FA levels in serum that indicate onset of NAFLD and metabolic syndrome.
Additionally, serum ketone levels were reduced compared to wild-type controls. In
contrast, FGF21-injected mice showed comparable levels of serum TG and free FA
to wild-type controls. These mice also showed increased serum ketone levels
compared to both wild-type and CrebH-null mice with vehicle treatment. These
results indicate that FGF21 is the major downstream factor targeted by CREBH in
regulating TG and FA metabolism. This also shows that the capacity of FGF21 to
treat hyperlipidemia extends to diseases that are caused by CREBH deficiency.
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Figure 28. Infusion of recombinant FGF21 protein partially rescued NASH phenotype
of the CrebH-null mice after the AHF diet. CrebH-null (KO) and wild-type (WT) control
mice were fed with AHF diet for 6 months before they were injected i.p. with purified
recombinant FGF21protein or vehicle once a day for 8 days. Histologic staining
analysis of liver tissue sections from the wild-type and CrebH-null mice after 8 days of
FGF21 protein or vehicle treatment. (A) Oil-red O staining of hepatic lipid droplets. (B)
Hematoxylin and eosin (HE) staining of liver tissue sections. (C) Sirius red staining of
hepatic collagens. Magnification: 200x.
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FGF21 protein injection was also able to rescue hepatic symptoms of NASH.
Oil Red O staining of lipid droplets in liver tissue showed that the AHF-diet regimen
was successful in inducing NAFLD in vehicle-treated CrebH-null mice (Figure 28A).
This effect was ameliorated CrebH-null mice that were injected with FGF21 protein.
Enzymatic analysis of liver TG levels confirmed reduced TG content in FGF21injected CrebH-null mice (Figure 29A). Hepatocyte ballooning was reduced in CrebHnull mice after FGF21 treatment, as well (Figure 28B). This was corroborated by a
significant decrease in hepatocyte size (Figure 29B). Portal and lobular inflammation
were unaffected by FGF21 treatment CrebH-null mice (Figure 28B). Fibrosis
(assessed by Sirius Red staining of collagen) was not decreased in these mice, either
(Figure 28C). The long-term stress caused by AHF diet-feeding (6 months) may have
caused morphological changes that were unable to be overcome by the relatively
short treatment period (8 days). Effects of FGF21 injection were detectable from a
gross anatomical observation (Figure 30). CrebH-null mice that received FGF21
treatment displayed improved liver size and coloration compared to vehicle-injected
CrebH-null mice. Additionally, FGF21, as a potent metabolic hormone, modulates
lipid metabolism in adipose tissues (110-112).
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Figure 29. Administration of recombinant FGF21 protein reverses hepatic steatosis
phenotype developed in the CrebH-null mice under the AHF diet. (A) Levels of
hepatic TG in the livers of the wild-type (WT) and CrebH-null mice treated with
recombinant FGF21 protein (FGF21) or vehicle. (B) Fold change of hepatocyte sizes
in the livers of the wild-type and CrebH-null mice administrated with recombinant
FGF21 protein or vehicle. For the tissue section from each animal, sizes of
hepatocytes from 3 representative tissue areas per mouse were calculated to obtain
the average hepatocyte size for each treatment group. Each bar denotes the mean ±
SEM (n=5 WT or KO mice treated with vehicle and 4 KO mice treated with FGF21). *
P ≤ 0.05.

Figure 30. Gross anatomical inspection of liver morphology after FGF21 protein
administration.
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Because NASH typically presents with glucose intolerance and insulin
resistance, we assessed the effect of FGF21 protein injection on the improvement of
glucose tolerance in CrebH-null mice (64). GTT was performed and indicated
improved glucose tolerance in CrebH-null mice injected with FGF21 compared to
CrebH-null mice injected with vehicle control (Figure 31). These results not only
confirm that FGF21 is the major CREBH-target in regulating lipid metabolism, but
also indicate that FGF21 protein administration may be an effective treatment to
rescue NASH and its related metabolic symptoms.

Figure 31. GTT analysis with CrebH-null (KO) and wild-type (WT) control mice after
administration with vehicle PBS or FGF21 protein. KO and WT control mice were fed
with AHF diet for 6 months before they were injected i.p. with purified recombinant
FGF21protein or vehicle once a day for 6 days. Mice were subjected to fasting blood
sample collection and glucose tolerance test after 12-hour fasting Glucose tolerance
tests of the CrebH-null and wild-type control mice after administration of the FGF21
protein or vehicle. Animals were fasted for 12 hours before being infused with 1 mg
D-glucose per gram body weight. Each bar denotes the mean ± SEM (n = 5 WT or
KO mice treated with vehicle and 4 KO mice treated with FGF21).
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4.4 Discussion
Having characterized the molecular mechanism by which CREBH regulates
Fgf21 expression, we sought to delineate the functional impact of the CREBH-FGF21
regulatory axis in lipid homeostasis and metabolic disorders. CrebH-null mice
develop profound hyperlipidemia and NASH under the AHF diet (Figure 5) (12).
Therefore, the AHF-fed CrebH-null animal model is a perfect model system for
evaluating therapeutic potential of FGF21 protein treatment in metabolic symptoms
associated with impaired lipid metabolism. Through administration of recombinant
FGF21 protein to the CrebH-null mice, we demonstrated the effects of FGF21
treatment in decreasing blood TG and FA of the CrebH-null mice (Figure 27). FGF21
treatment can partially rescue hepatic inflammation and fibrosis in the CrebH-null
mice after the AHF diet (Figures 28 and 29). These results confirm that FGF21 is a
major target of CREBH in regulating lipid homeostasis under metabolic stress. Our
findings also identify FGF21 as a potential therapeutic agent in the treatment of
NASH.
The significance of these findings is also implicated by the fact that the
transcriptional regulation of Fgf21 by CREBH that we have outlined is reflected at the
physiological level. The CREBH-dependent increase in serum FGF21 levels coupled
with the ability of circulating FGF21 to induce signaling at a systemic level opens up
the possibility that CREBH may have a more direct role in modulating metabolism
outside of the liver.
CrebH-null mice are susceptible to diet-induced NASH. FGF21 has been
shown to rescue metabolic disorders in diet-induced disease models. We performed
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similar experiments using our CrebH-null model of NASH. Previous reports of FGF21
protein injection experiments indicate that this procedure induced significant weight
loss in mice that have been fed a high-fat diet. In our study, administration of FGF21
protein to the CrebH-null mice for 8 days led to a modest loss in body weight (Figure
26B). This is likely due to the relatively short time frame of the treatment over which
the experiment was carried out. It is likely that a more sustained regimen would
produce more drastic weight loss in our mouse model. To further support the
effectiveness of the treatment, serum FGF21 levels radically increased in mice that
received the rescue treatment (Figure 26A). The ability of the FGF21 treatment to
rescue the hyperlipidemia and hepatocyte size increase present in the CrebH-null
disease model mice implicates that CREBH can significantly mediate hepatic
metabolic state by modulating Fgf21 expression.
The effectiveness of the treatment in reversing the hyperlipidemia associated
with our model shows that these effects can reach the circulating serum and have
systemic effects. Functional mutations in CREBH have already been identified as a
contributing factor in hypertriglyceridemia in human patients (70). FGF21 is currently
a topic of interest as a therapeutic option. The findings from my rescue experiment
confirm the pleiotropic effects of exogenous FGF21 administration on lipid
metabolism and its promising therapeutic potential in metabolic disorders. Our study
offers important evidence for FGF21 as a potential treatment option for patients
suffering from hypertriglyceridemia linked to CREBH mutation.
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CHAPTER V: Conclusions and Significance
CREBH is emerging as a key player in hepatic response to metabolic stress.
This work identifies the phenotypic effect of CrebH deficiency under various
metabolic stress conditions. Previous studies suggested a major role for CREBH in
lipid metabolism and gluconeogenesis under high-fat diet-induced stress. However,
the method by which CREBH regulates complex metabolic programs involved in
multiple pathways under metabolic stress remains elusive. My studies established
that CREBH plays this role under fasting-induced stress and that the length of the
fast affects the regulation. Additionally, it was demonstrated that CREBH regulates
ketogenesis by targeting Bdh1 and Hmgcs2. Importantly, Fgf21 was identified as a
target of CREBH. Because of the importance of FGF21 as a metabolic hormone, we
focused our attention on defining the mechanism of this regulation. At the molecular
lever, CREBH interacts with PPARα to activate FGF21 expression through a multilayered regulatory mechanism. CREBH and PPARα regulate each other at the
transcriptional level in liver upon metabolic stress, such fasting or AHF diet (Figure 20
and 21). Metabolic stress-induced expression of Fgf21 requires both CREBH and
PPARα. The coordination between CREBH and PPARα in regulating Fgf21
expression involves protein-protein interaction during fasting or AHF diet-feeding
(Figure 25). Inspection of the Fgf21 promoter led to the recognition of the juxtaposed
CRE and PPRE binding sites where CREBH and PPARα are enriched under
metabolic stress (Figure 15). Through protein-protein and protein-DNA interactions,
CREBH and PPARα function in synergy to activate expression of the Fgf21 gene.
CREBH and PPARα appear to act as binary trans-activators that regulate each other
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for their expression and interact with each other for their function. In the future,
understanding how CREBH interacts with other proteins to modify its transcriptional
effects will be key to understanding the regulatory mechanism of CREBH in stress
response.
An important part of my work is the demonstration of the therapeutic potential
of FGF21 in the treatment of NASH and its common comorbidities. By administering
the AHF diet to CrebH-null mice, previous studies in our lab have generated a
disease model of NASH that is dependent on CREBH deficiency (12). CrebH-null
mice develop profound hypertriglyceridemia, hypoketonemia, and NASH under the
AHF diet. Therefore, the AHF-fed CrebH-null mouse is a perfect model system for
evaluating the therapeutic potential of FGF21 protein as a treatment option in NASH
and its associated symptoms. Owing to the severity of NASH and associated
metabolic dysfunction, as well as the increasing interest in FGF21 as a therapeutic
option, we chose to treat our disease model mice using recombinant human FGF21
protein. CrebH-null mice showed a partial recovery from the NASH state in response
to this treatment. Previous studies have used exogenous FGF21 protein to treat
metabolic disease model animals (82, 86). However, the effectiveness of FGF21
protein in the treatment of NASH and CREBH-deficiency were novel findings.
Because this treatment lowered serum TG levels and human CREBH deficient
patients suffer from hypertriglyceridemia, this discovery is pertinent to the
management of human disease.
This body of work was created with the goal of understanding of the
mechanism of CREBH regulatory action. Based on my findings, I can make three
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conclusions that make strong headway in achieving this goal (Figure 32). First,
CREBH is essential for hepatic adaptation to metabolic stress, particularly for the
response involved in lipid metabolism. Second, FGF21 plays a role in mediating
these effects and CREBH works in tandem with PPARα to promote Fgf21 expression.
Third, the metabolic disease phenotype observed in CrebH-deficient mice under an
AHF diet is relieved by exogenous FGF21 administration. Therefore, these findings
extend the relationship between the nuclear receptors and ER-associated transactivators in regulating energy metabolism.
However, my research does not fully describe the role of CREBH in metabolic
regulation. Much work remains to be done in this field in order to meet that goal. Of
particular importance is the role of CREBH in the regulation of metabolism under
high-sucrose diet-induced stress. Fasting and high-fat diet-feeding activate some
common response pathways, such as lipolysis and ketogenesis (113-116). Highsucrose diet-feeding activates a distinct set of responses, including glycolysis and
lipogenesis(117). The potential activation of CREBH by a stress factor that differs so
fundamentally from previously described inducers greatly broadens the prospective
range of CREBH-mediated metabolic control. Addressing these questions in the
future will provide novel insights into the key transcriptional programs that control
energy homeostasis and has important implications in the understanding and
treatment of metabolic disease.
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Figure 32. Proposed model of CREBH-mediated Fgf21 regulation. Under fasting or
high-fat diet feeding conditions, CREBH associates with PPARα at the Fgf21
promoter region under metabolic stress. Fgf21 is up-regulated at the RNA and protein
levels. Lipid and ketone metabolism pathways are activated. The original metabolic
stress is alleviated by the action of the CREBH-PPARα-FGF21 regulatory axis.
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APPENDIX A

Gene name

Forward primer

Reverse primer

CrebH
PPARα
Apoc2
Apoa4
Fgf21
ApoA5
Bdh1
Hmgcs2
Ldha

TCGTGCCAGTGCGAGTGT
GAAGGGCACACGCGTGCGAGTTTTCAG
CTCTGCTGGGCACGGTGCA
GCATCTAGCCCAGGAAACTG
GTGTCAAAGCCTCTAGGTTTCTT
TCCTCGCAGTGTTCGCAAG
TGACACCCGTCGGACCTAC
GAAGAGAGCGATGCAGGAAAC
TGTCTCCAGCAAAGACTACTGT

AGCCACGCGGGATGC
CTGTGATGACAACGTCTTGTTCCCGAACT
GCCGCCGAGCTTTTGCTGTAC
ATGTATGGGGTCAGCTGGAG
GGTACACATTGTAACCGTCCTC
GAAGCTGCCTTTCAGGTTCTC
TTCTCAGTCGGTCACTCTTCA
GTCCACATATTGGGCTGGAAA
GACTGTACTTGACAATGTTGGGA

Sequence information for primers used in quantitative real-time PCR studies.
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APPENDIX B
Human FGF21 Promoter
1
61
121
181
241
301
361

CGAGTGGAGC
CAGGCTGCCG
GTCTCCGATC
CCTAGTCACT
GCACTGCACG
CACGCCGTCA
CACCTAATTA

GATCGTCCGC
CCGGAGCGCG
TCCCACACCC
CCTTTTGGGG
AAGGCAACCA
GCGGGGGCCG
AAGCATTTTC

CCTCTGCCGC GTCCTCCTGG GGGATGGAGA ACCTGTTTGC
CGAGGGCCTC CAGCCTGCAG GTGCTCCCGC GCCCACCAGG
CCCGCCTCAC CGTCCACACT CAAATTCCAG AATCCCAGCC
AATTCTAGGG TCCCGTGCCA AACTGCTACT TTCCAGACCT
TTCCAAGGCT GGAGACCGGA GTGGAACAGG GTCTGTTTCC
TGGCTGCCGG CGCCAGAGAC AAAGGCCTCT GCCCGCTTGT
TCTGGTCCAA GGCCCACCTC CAGCATCGCC AACCCCGAGC
CAGGTT CCGGGTGGAG GTCGT
421 AGGGCAGGCT AACGTAGGGT CCAGCCCTAC GGGGCTTTGC GGGTGGGTGT TCTTCCCCTG
481 TGAGGAGAGG AGAGATTGTA AGAAATAAAG ACACAAGACA AAGAGATAAA GAGAAAACAG
541 CTGGGCCCGG GGGACCACTA CCATCAAGAC GCAGAGACCG GTAGTGGCCC CGAATGGCTG
--------------------------------------------------------------------------------------------------------------------------------2641 AGATGGTCCA AGAGGTGGTT TTTCCAGGAG CCCAGCACCC CTCCTCCCTC CGACTCAGGT
2701 GCTTGAGACC CCAGATCCTT CTCTCTGAGA CTCAGGAATG TGGGCCCCCA GCCCCTTTCA
2761 CCTGGGTCCC AGCTAACCCG ATCCTCCCCT CCCTCATCCC CTAGACCCAG GAGTCTGGCC
2821 CTCCATTGAA AGGACCCCAG GTTACATCAT CCATTCAGGC TGCCCTTGCC ACGATGGAAT
2881 TCTGTAGCTC CTGCCAAATG GGTCAAATAT CATGGTTCAG GCGCAGGGAG GGTGATTGGG
PPRE2

PPRE1

2941 CGGGCCTGTC TGGGTATAAA
3001 CTGTCAGCTG AGGATCCAGC
CG
3061 ACCTGGACAA CTGGAATCTG

TTCTGGAGCT
CGAAAGAGGA
GCTTTCTCCT
GCACCAATTC

3121
3181
3241
3301
3361
3421
3481
3541
3601
3661
3721
3781
3841
3901
3961

CGAGCCATTG
GCTGGCTGGT
CCTGCAATTC
AGAAGCCCAC
CGAAAGTGAG
CTGGGTCTGA
GGGGATCTGG
AGGGAGGAGG
CTCTTGGGTT
GGCTTTGGCT
CAGGGCTGGG
GAGAGGTCCT
TGAAGCCGGG
CAGATGGGGC
CCTCCTATAT

CCGGAGATCA
TCAGGACTGT
ATCCCTGACT
ACAGATGATG
GGCGCTGCTG
GGGGCTGTGG
GGTCTGAGGG
GATCTGGGCC
GGAGGGGCTG
TTGGGTCTGA
AGGCTGTGGG
GGTGGGACAG
TCTCCTGCAG
CAGGTTCCTG
TCCTCACCAC

CCTGAGGACC
GGGTTTCTGT
CCAGTCCTCT
CCCAGCAGAC
ACCAGAGCCC
GTCTGGATTC
AGGAGGGGCT
CCTGGGTCTG
GGGGTCTGGA
GTTGGGAGGG
CTTGGACTCC
TCCCGGGTGG
CTGAAAGCCT
TGCCAGCGGC
CCACCATGCT

CREB

TCTGCATCTA
GCCAGGCACT
CGGTCCG
TAAACCACTC
CDS
ATGGACTCGG
CTTCTGCTGG
GGGGGCCAAG
CTGGAGATCA
TGTGGGCCAG
GGGAGGAGGG
ACTCCTGGGT
GGCTGGGTCT
TGAAGAAGGA
TGGGCTTCTC
ACAGAGCCGG
CGAACCACCT
AGTTATTCAA
CCTGTATGGA
GTCGCCCTCA

TCCCAAAAAA CAAGGGTGTT
CAGGCCACCT GAGTCTACTC
AGCTTCTCCG AGCTCACACC
ACGAGACCGG
GAGCCTGCCA
TCCGGCAGCG
GGGAGGATGG
AGCCTGGGTC
GCTGGGGGCC
CTGAGGGAGG
GGACCCCTGG
AGGGCTGGGG
CTGGGTCTGA
ATGGTGGGAC
TATCGCTTTC
ATCTTGGGAG
TCGGTGAGTT
C

GTTCGAGCAC
GGCACACCCC
GTACCTCTAC
GACGGTGGGG
TGAGGGAGGA
TTGGCCCCTG
AGGGGCTGGG
GTCTGAGGGA
TCCTGGACTC
GGGAGGAGGT
AGAGTCGGGT
ACCCCTTAGG
TCAAGACATC
TCCAGGACCC

hFGF21 ChIP (CREBH)-B
hFGF21 ChIP (NS)-B: ChIP negative control primers

Sequence of the human FGF21 gene promoter highlighting potential CREBH and
PPARα binding sites, FGF21 ChIP primers, and ChIP negative control primers.
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ABSTRACT
THE ROLE OF CREBH IN HEPATIC ENERGY REGULATION UNDER
METABOLIC STRESS
by
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Degree: Doctor of Philosophy
Lipid metabolism is tightly regulated by nuclear receptors, transcription factors,
and cellular enzymes in response to nutritional, hormonal, and stress signals.
Hepatocyte specific, cyclic AMP responsive element-binding protein (CREBH) is a
transcription factor that is preferentially expressed in the liver and localized in the
endoplasmic reticulum (ER) membrane. CREBH is known to be activated by ER
stress, inflammatory stimuli, and metabolic signals to regulate hepatic acute-phase
response, lipid metabolism, and glucose metabolism. In my thesis research, I have
characterized the roles and mechanisms of CREBH in these functions, as well as the
overall phenotype of CrebH-null mice. I demonstrated that CREBH interacts with
peroxisome proliferator-activated receptor α (PPARα) to regulate expression of the
genes involved in lipolysis, FA oxidation, and ketogenesis by activating fibroblast
growth factor 21 (FGF21), a hepatic hormone that regulates whole-body energy
homeostasis. Gain- and loss-of-function analyses indicated that CREBH and PPARα
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regulate each other for their expression. Activated CREBH protein interacts with
PPARα under fasting or metabolic diet, and both factors are required for induction of
the FGF21 gene. CREBH and PPARα bind to integrated CREH-PPARα binding
motifs in the FGF21 gene promoter across mammalian species. CREBH and PPARα
function in synergy to activate the FGF21 gene promoter. Administration of
recombinant human FGF21 protein can rescue hypertriglyceridemia and
hypoketonemia and, partially, nonalcoholic steatohepatitis (NASH) in the CrebH-null
mice developed under an atherogenic high-fat diet, corroborating the role of CREBH
in regulating FGF21. In summary, my research demonstrated the transcriptional
mechanism for CREBH in regulating lipid metabolism by activating FGF21. In
particular, the functional interaction between CREBH and PPARα in regulating
FGF21 may represent an important transcriptional coactivation mechanism in
maintaining lipid homeostasis under metabolic stress.
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